Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMRN is 3.25M and currently, short sellers hold a 0.27% of that float. On May 23, 2025, IMRN’s average trading volume was 14.76K shares.
IMRN) stock’s latest price update
Immuron Limited ADR (NASDAQ: IMRN)’s stock price has gone rise by 10.91 in comparison to its previous close of 1.65, however, the company has experienced a 7.26% increase in its stock price over the last five trading days. globenewswire.com reported 2025-04-10 that Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year – highest sales in history March 2025 Quarter AUD$1.3 million up 2% on prior year March 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior year March 2025 Year to Date AUD$3.7 million up 34% on prior year North America March 2025 Quarter AUD$0.5 million up 28% on prior year March 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Flavio Palumbo, Chief Commercial Officer said, “For the first time, Immuron has exceeded A$5 million in sales – our highest fiscal year sales ever!
IMRN’s Market Performance
Immuron Limited ADR (IMRN) has experienced a 7.26% rise in stock performance for the past week, with a 5.78% rise in the past month, and a -8.21% drop in the past quarter. The volatility ratio for the week is 6.95%, and the volatility levels for the past 30 days are at 4.78% for IMRN. The simple moving average for the past 20 days is 0.64% for IMRN’s stock, with a -12.02% simple moving average for the past 200 days.
IMRN Trading at 2.25% from the 50-Day Moving Average
After a stumble in the market that brought IMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.24% of loss for the given period.
Volatility was left at 4.78%, however, over the last 30 days, the volatility rate increased by 6.95%, as shares surge +6.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.81% upper at present.
During the last 5 trading sessions, IMRN rose by +7.26%, which changed the moving average for the period of 200-days by -26.80% in comparison to the 20-day moving average, which settled at $1.8184. In addition, Immuron Limited ADR saw 7.65% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for IMRN
Current profitability levels for the company are sitting at:
- -0.97 for the present operating margin
- 0.67 for the gross margin
The net margin for Immuron Limited ADR stands at -1.12. The total capital return value is set at -0.61. Equity return is now at value -52.79, with -45.93 for asset returns.
Based on Immuron Limited ADR (IMRN), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -58.03. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1770.77.
Currently, EBITDA for the company is -6.88 million with net debt to EBITDA at 1.29. When we switch over and look at the enterprise to sales, we see a ratio of 1.12. The receivables turnover for the company is 5.7for trailing twelve months and the total asset turnover is 0.54. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.80.
Conclusion
To wrap up, the performance of Immuron Limited ADR (IMRN) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
